Why Your NPN Application Gets Rejected — And How to Fix It Before Submission

More than 110,000 natural health products carry a valid product licence number in Canada right now. That figure sounds like a smoothly running system — but anyone who’s worked through an NPN submission knows the reality is considerably more complicated. Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) regularly stops, pends, or rejects applications, and the reasons follow predictable patterns that experienced regulatory professionals recognize immediately.

After working through dozens of NPN submissions with clients across supplement manufacturers, importers, and traditional herbal producers, the same categories of problems surface again and again. Understanding them before you file is worth more than any post-rejection correction strategy.

What Health Canada Is Actually Evaluating in an NPN Submission

The Natural Health Products Regulations (NHPR, SOR/2003-196), which came into force on June 1, 2004, define the evidence and documentation requirements for every product licence application. But the regulations alone don’t spell out what a complete submission looks like in practice — that lives in Health Canada’s guidance documents, and interpreting those documents correctly is where many applicants fall short.

At its core, NNHPD reviewers are assessing three things: evidence that the product is safe, evidence that it’s effective for the claims made, and evidence that the product specification is sufficient to ensure consistent quality across every manufactured lot. Each pillar has specific documentation requirements, and a weakness in any single area can stall the entire application.

Health Canada uses three evidence classes for NPN applications:

• Class I: Well-established use supported by peer-reviewed clinical data (e.g., vitamins with recognized Dietary Reference Intakes)
• Class II: Traditional use — 150 years of historical use documented in authoritative sources, with at least 50 years of that use traceable to Canada
• Class III: Modern clinical evidence for products making specific health claims beyond traditional use

Class I applications carry a 30-calendar-day review target. Class III submissions, where reviewers scrutinize randomized trial data and systematic reviews, have a 180-day target — and in practice, complex submissions have historically run considerably longer when documentation arrives incomplete at first filing.

The Five Most Common Reasons NPN Applications Fail

1. Claims that don’t match the evidence class

This is the single most frequent problem. An applicant wants to market a botanical product with a modern efficacy claim — say, “clinically shown to support healthy blood glucose” — but files under Class II traditional use evidence. The claim and the evidence class are fundamentally mismatched, and NNHPD will flag it immediately.

If you’re making a modern health claim, you need modern clinical evidence: randomized controlled trials, peer-reviewed meta-analyses, or systematic reviews that directly support the claim as worded on the label. “Supports healthy blood sugar” and “clinically shown to support healthy blood sugar” are not equivalent claims in Health Canada’s framework, even if they sound similar in a consumer marketing context. The word “clinically” triggers a Class III evidence expectation.

2. Product specifications that aren’t testable

Every NPN submission requires product specifications — potency, purity, and quality parameters for each medicinal ingredient. The issue isn’t usually that specifications are missing; it’s that they’re written in ways that can’t be verified by analytical testing.

A specification that says “contains standardized extract” without defining the active marker compound, the acceptable concentration range, and the validated test method is, for regulatory purposes, unverifiable. Health Canada expects you to define: an identity test (botanical, chemical, or microbiological), a quantitative assay with acceptance criteria, and the relevant pharmacopoeia reference where one exists. USP, the Canadian Food Chemicals Codex, and Ph.Eur. monographs are all accepted sources.

This matters because a product licence is only as defensible as its specification. If you can’t test it, you can’t claim consistent quality under the NHPR’s Good Manufacturing Practices framework — and Health Canada knows it.

3. Non-compliant labelling

The NHPR’s Part 5 has detailed labelling requirements, and submissions that include product labels (mandatory for the application) are frequently pended for corrections. Common issues include:

• Recommended conditions of use that contradict the evidence (dosing higher than what the cited clinical studies actually used)
• Missing or incorrect risk information, cautions, and warnings required for specific ingredient categories — particularly for products intended for children, pregnant women, or individuals on medications
• Non-bilingual labelling: both English and French are required on any Canadian market label
• Claim language that extends beyond what Health Canada has approved for the ingredient at the proposed dose

The bilingual requirement catches importers particularly often. Products manufactured in the United States or Europe with English-only labels need Canadian-compliant relabelling before any product licence can issue. A 2-column bilingual format isn’t optional — it’s a condition of market entry.

4. Inadequate evidence for traditional use claims

Class II applications require you to establish a documented tradition of use. That sounds straightforward, but NNHPD expects authoritative bibliographic references — not manufacturer-supplied monographs or websites. The standard accepted sources include the WHO Monographs on Selected Medicinal Plants, recognized pharmacopoeias, and peer-reviewed ethnobotanical literature from established journals.

One detail that consistently trips up applicants: the 50-year Canadian use requirement doesn’t mean the ingredient needs to be Canadian in origin. It means there must be documented evidence of traditional use within Canada for at least 50 years. For many traditional Chinese medicine botanicals or Ayurvedic herbs, Canadian-specific documentation is genuinely sparse. Assuming that a well-known traditional herb automatically qualifies is a mistake that delays Class II submissions by months.

5. Missing or misformatted product master file authorizations

If your formulation relies on ingredients for which no Health Canada Product Master File (PMF) exists, you need to generate one or obtain written authorization to cross-reference an existing file held by a supplier or manufacturer. Suppliers who hold PMFs for their own ingredients can grant you access — but that authorization must be a formal letter included in your submission package.

Applications that reference a supplier’s PMF without the authorization letter are stopped at administrative screening, before a substantive reviewer ever looks at them. That can add 4–8 weeks to a timeline that’s already stretched. It’s a procedural issue, not a scientific one — which makes it particularly frustrating because it’s entirely preventable.

How to Build a Submission That Moves Through Review

The NNHPD has made significant guidance available through Health Canada’s website, including the Product Licence Application Checklist and evidence-class-specific templates. Working from these documents isn’t optional — reviewers evaluate submissions against them, and deviations without justification draw questions.

Pre-submission specification audit. Before you file, have your product specifications reviewed against the relevant pharmacopoeia monographs and Health Canada’s guidance on NHP product specifications. An analytical lab with experience in Canadian NHP testing can identify gaps before they become formal deficiencies. Specifications referencing validated in-house methods need supporting validation data that demonstrates the method is scientifically sound and capable of detecting the claimed potency range across the expected concentration window.

Claims matrix construction. Map every claim on your label to a specific reference and dose level in your supporting evidence. Build a table — each claim, the supporting citation, the dose used in that citation, and your proposed dose. Reviewers won’t ask you to submit this document, but building it forces you to identify the mismatches before NNHPD does. This exercise alone catches the majority of evidence-class mismatches we see in client submissions.

Bilingual label review by a qualified Canadian French translator. Don’t rely on machine translation for regulatory labels. The French text needs to reflect the same approved claims and conditions of use as the English version — exactly. Regulatory nuance gets lost in automated translation, and a label that accurately says one thing in English but implies something different in French creates a compliance problem that isn’t always obvious until a reviewer flags it.

Manufacturing site licence verification. Your product licence is issuable only if the manufacturing site holds a current, valid Site Licence under the NHPR. Confirm the site licence includes the appropriate dosage form categories for your product and covers the specific manufacturing activities being performed. Site licences require annual renewal, and an expired licence at a contract manufacturer can invalidate an otherwise complete NPN application — even if your documentation is excellent.

Realistic Timelines — And What Drives Them

Health Canada publishes target review times, but first-time applicants consistently experience longer timelines, particularly when submissions arrive with even minor deficiencies. Class I submissions filing under recognized monograph conditions can clear in 30–60 days if documentation is clean. Class II submissions typically run 3–6 months in practice. Class III submissions with novel clinical evidence can reach 6–18 months, especially if NNHPD issues a Notice of Deficiency (NOD) requiring additional information.

An NOD essentially resets the substantive review clock. Once received, you have 90 days to respond — and the quality of that response determines whether the application continues forward or is stopped entirely. Organizations that treat an NOD response as a compliance project (systematic, documented, led by a regulatory professional who understands what the reviewer’s specific question is really asking) consistently fare better than those who respond reactively with incomplete answers.

The most effective cost management strategy in NPN licensing isn’t finding shortcuts. It’s investing in a complete, well-documented submission from day one. Corrections after an NOD are almost always more expensive than the regulatory review that would have caught the issue pre-filing — and the time cost compounds in ways that affect your product launch timeline, your inventory planning, and your commercial relationships.

If you’re entering the Canadian NHP market for the first time, or if your current portfolio has licences approaching amendment territory, an internal audit of your NPN files against current NNHPD guidance is a sensible first step. Requirements have been updated since the NHPR came into force in 2004, and some older licences reflect guidance that no longer aligns with current reviewer expectations.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Supplement and NHP ingredient testing with full COA support — ISO 17025-accredited laboratory testing for raw material qualification and finished product specifications used in Canadian NPN submissions
• European market entry for health product manufacturers — Regulatory guidance for Canadian NHP companies looking to expand into EU cosmetics and food supplement frameworks